Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

Researchers reveal immune machinery that goes awry to trigger neutrophilic dermatosis

Researchers reveal immune machinery that goes awry to trigger neutrophilic dermatosis

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

Psoriatic arthritis patients experience multiple symptoms that can make diagnosis difficult, survey reveals

Psoriatic arthritis patients experience multiple symptoms that can make diagnosis difficult, survey reveals

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Almirall launches ‘Not Today’ story to raise awareness about psoriasis

Almirall launches ‘Not Today’ story to raise awareness about psoriasis

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Penn State dermatologist clarifies common myths about psoriasis

Penn State dermatologist clarifies common myths about psoriasis

Research finding opens door to new treatment options for inflammatory rheumatism

Research finding opens door to new treatment options for inflammatory rheumatism

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Review sheds new light on link between smoking habits and psoriasis

Review sheds new light on link between smoking habits and psoriasis

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis